http://www.vanleeuwenhoeckresearch.com/(c) 2009, Van Leeuwenhoeck Research All rights reserved.5You can subscribe to this RSS Feed to keep updated on the latest news on Van Leeuwenhoeck Research.http://us.rd.yahoo.com/finance/external/tsmfe/rss/SIG=1314t9rqt/*http%3A//www.thestreet.com/_yahoo/story/10699212/1/facet-biotech-stock-soars-on-abbott-bid.html?cm_ven=YAHOO&cm_cat=FREE&cm_ite=NAWed, 10 Mar 2010 04:50:00 GMTWed, 10 Mar 2010 05:12:26 GMThttp://us.rd.yahoo.com/finance/external/xbwsj/rss/SIG=12srsroh6/*http%3A//blogs.wsj.com/health/2010/03/09/intermunes-lung-drug-gets-backing-from-fda-panel/?mod=yahoo_hsWed, 10 Mar 2010 04:23:00 GMTWed, 10 Mar 2010 05:12:26 GMTSAN DIEGO----Coughlin Stoia Geller Rudman & Robbins LLP today announced that a class action has been commenced in the United States District Court for the Northern District of California on behalf of purchasers of Medivation, Inc. common stock during the period between July 17, 2008 and March 2, 2010, inclusive .http://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/bw/100309/20100309007149.html?.v=1Wed, 10 Mar 2010 03:46:00 GMTWed, 10 Mar 2010 05:12:26 GMThttp://us.rd.yahoo.com/finance/external/wsj/rss/SIG=12i1kkikp/*http%3A//online.wsj.com/article/SB10001424052748704784904575112090416314912.html?ru=yahoo&mod=yahoo_hsWed, 10 Mar 2010 03:31:00 GMTWed, 10 Mar 2010 05:12:26 GMThttp://us.rd.yahoo.com/finance/external/cbsm/rss/SIG=11kitjnkn/*http%3A//www.marketwatch.com/News/Story/Story.aspx?guid=%7b67F42578-3850-4571-ABCF-D75A52184494%7d&siteid=yhoof2Wed, 10 Mar 2010 03:19:00 GMTWed, 10 Mar 2010 05:12:26 GMTLife Technologies Corp. Chairman and CEO Gregory Lucier's compensation fell 60 percent to just over $4.5 million in 2009 on a lack of stock awards, according to an Associated Press calculation of figures disclosed in a regulatory filing.http://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/ap/100309/us_life_technologies_executive_compensation.html?.v=1Wed, 10 Mar 2010 03:08:00 GMTWed, 10 Mar 2010 05:12:26 GMThttp://us.rd.yahoo.com/finance/external/cbsm/rss/SIG=11kitjnkn/*http%3A//www.marketwatch.com/News/Story/Story.aspx?guid=%7b2EF7DEE0-0C4A-4F8D-8711-BDD7DF886FF2%7d&siteid=yhoof2Wed, 10 Mar 2010 03:06:00 GMTWed, 10 Mar 2010 05:12:26 GMThttp://us.rd.yahoo.com/finance/external/bizj/rss/SIG=12ashv7vu/*http%3A//sanjose.bizjournals.com/sanjose/stories/2010/03/08/daily35.html?ana=yfcpcWed, 10 Mar 2010 03:05:00 GMTWed, 10 Mar 2010 05:12:26 GMThttp://us.rd.yahoo.com/finance/external/video/cnbc/rss/SIG=113mb0hsu/*http%3A//www.cnbc.com/id/15840232?play=1&video=1436194606&__source=yahoo%7Cheadline%7Cquote%7Cvideo%7C&par=yahooWed, 10 Mar 2010 02:54:00 GMTWed, 10 Mar 2010 05:12:26 GMTAbbott and Facet Biotech Corporation announced today a definitive agreement for Abbott to acquire Facet, enhancing Abbott's early- and mid-stage pharmaceutical pipeline.  Abbott will acquire Facet for $27 per share in cash for a net transaction value of approximately $450 million, which includes a purchase price of approximately $722 million less Facet's projected cash and marketable securities at closing of approximately $272 million.  http://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/prnews/100309/cg67861.html?.v=1Wed, 10 Mar 2010 02:52:00 GMTWed, 10 Mar 2010 05:12:26 GMTFederal health advisers on Tuesday voted in favor of an experimental drug from InterMune Inc., despite mixed evidence of whether it provides significant benefits for patients with a rare lung disease.http://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/ap/100309/us_intermune_fda_panel.html?.v=4Wed, 10 Mar 2010 02:44:00 GMTWed, 10 Mar 2010 05:12:26 GMTInterMune, Inc. announced today that the U.S. Food and Drug Administration's Pulmonary-Allergy Drugs Advisory Committee voted 9-3 to recommend approval of Esbriet® for the treatment of patients with idiopathic pulmonary fibrosis to reduce decline in lung function.  http://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/prnews/100309/sf67688.html?.v=1Wed, 10 Mar 2010 02:21:00 GMTWed, 10 Mar 2010 05:12:26 GMThttp://us.rd.yahoo.com/finance/external/wsj/rss/SIG=12i8snava/*http%3A//online.wsj.com/article/SB10001424052748704784904575111951663431646.html?ru=yahoo&mod=yahoo_hsWed, 10 Mar 2010 02:09:00 GMTWed, 10 Mar 2010 05:12:26 GMTAnadys Pharmaceuticals, Inc. announced today that it will present at the ROTH 22nd Annual OC Growth Stock Conference on Tuesday, March 16, 2010 at 3:30 p.m. PDT .  The conference is being held at the Ritz-Carlton in Laguna Nigel, California.  Steve Worland, Ph.D., President and Chief Executive Officer of Anadys, will provide an overview of Anadys and its clinical development programs, ANA598 and ANA773.http://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/prnews/100309/la67116.html?.v=1Wed, 10 Mar 2010 02:05:00 GMTWed, 10 Mar 2010 05:12:26 GMTTranscept Pharmaceuticals, Inc. , a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that it plans to release fourth quarter and full year 2009 financial results on March 23, 2010 after the close of the market.  At 5:00 p.m.http://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/prnews/100309/sf67758.html?.v=1Wed, 10 Mar 2010 02:05:00 GMTWed, 10 Mar 2010 05:12:26 GMT